0001213900-26-037687
SEC filingFY2025 delivered positive net income for NewGenIvf Group, offsetting steep core operating declines and a significantly widened annual operating loss.
FY2025 operating results were pressured by weak domestic demand tied to the prolonged property sector downturn, leading to a 13% YoY decline in total revenue to $4.7M. Gross profit fell 47.7% YoY to $955.8K, bringing full-year gross margin to 20.2% as cost of service delivery outpaced the rate of revenue decline. The operating loss widened 824% YoY to -$10.7M, aligned with management commentary that the company’s business growth efforts have been costlier than initially projected, with revenue gains not yet sufficient to offset elevated operating spend. Competitive pressures also weighed on results, as expansion of existing fertility industry players risks eroding NewGenIvf’s existing market share and shrinking its traditional client pool.
Full-year FY2025 net income came in at $9.9M, a sharp reversal from the $524.6K net loss recorded in FY2024, representing a 1983.1% YoY improvement. Diluted earnings per share for the period hit $3.04, up from -$0.64 per share in the prior fiscal year, a 575.0% YoY increase.
Management expects costs and expenses to continue rising in future periods as the company works to expand awareness of fertility services and grow the broader fertility market. If revenue does not increase commensurately with these rising costs, the company’s long-term profitability may be at risk. Key near-term operational risks include the potential for the Bangkok Metropolitan Authority to order the First Fertility PGS Center to cease operations if the facility cannot secure required registration, which would require costly and disruptive relocation of the clinic. Regulatory measures impacting THB liquidity and cross-border capital flows also add uncertainty to the company’s operating environment.